Pain Reduction in Chronic Lumbar Patients Using Spinal Cord Stimulation by Botros, David
Augsburg University 
Idun 
Theses and Graduate Projects 
8-10-2021 
Pain Reduction in Chronic Lumbar Patients Using Spinal Cord 
Stimulation 
David Botros 
Follow this and additional works at: https://idun.augsburg.edu/etd 
 Part of the Orthopedics Commons 








Pain Reduction in Chronic Lumbar Patients Using Spinal Cord Stimulation 
By  
David Botros, PA-S 
Advisor: Vanessa Bester, EdD, PA-C 
 
Paper Submitted in Partial Fulfillment  
Of the Requirements for the Degree 
Of Master of Science  
Physician Assistant Studies  




Spinal Cord Stimulation 
 
2 














Background: Spinal cord stimulation (SCS) is commonly used to treat chronic neuropathic pain. 
A common indication for the SCS is failed back surgery syndrome (FBSS). There are many 
interventional approaches to treating lumbar pain; however, the SCS may provide the greatest 
benefit in terms of health care utilization and overall pain relief to the patient.   
Objective: The goal of this paper is to assess the effectiveness of SCS compared to conventional 
therapies such as physical therapy, oral medications, radiofrequency ablations (RFA), epidural 
steroid injections (ESI), and intrathecal pain pumps (IT pain pump) in patients with chronic 
lumbar pain due to FBSS.  
Methods: A comprehensive literature review was conducted to determine the effectiveness of 
the SCS. Interventions to treat FBSS were identified from least invasive to most invasive. 
PubMed and Google Scholar were primarily used to search for relevant literature. The following 
terms were used for this review: “spinal cord stimulation,” “chronic low back pain,” 
“conservative treatments,” “costs and cost analysis,” and “failed back surgery syndrome.” 
Discussion: Treatment for chronic lumbar pain begins with minimally invasive treatments such 
as physical therapy and medication management, and then may progress to more invasive 
treatments such as ESI, RFA, or IT pain pumps. When compared to these therapies, the SCS was 
associated with favorable outcomes and found to be more cost effective. 
Conclusion: For the treatment of chronic lumbar pain, the majority of studies suggest SCS as 
potentially more cost effective and efficient than conventional therapies; however, a 
multidisciplinary approach may provide the greatest benefit. SCS therapy may yet play a role in 
mitigating the financial burden associated with chronic lumbar pain.   




Spinal cord stimulation (SCS) has been around since the late 1960s and was initially used to treat 
neuropathic pain in cancer patients. Today, the most common indication for SCS is failed back 
surgery syndrome (FBSS) followed by Chronic Regional Pain Syndrome (CRPS) in attempts to 
treat chronic intractable pain, with a majority of SCS implants going to FBSS patients.7 
Indications for back surgery include degenerative disc disease, spinal stenosis, spondylolisthesis, 
fractures, and tumors. FBSS is a frequently encountered disease following lumbar surgery. The 
diagnosis is made when chronic lumbar or leg pain is present after a successfully performed 
lumbar surgery and there is no specific etiology of the pain. More than 50,000 SCS devices are 
implanted each year.1 
 Estimates of the percentage of adults over the age of 18 who experience chronic lumbar 
pain during their lifetime ranges from 60-80%.7 The incidence increases with increasing age and 
female gender. Approximately 10% of individuals suffering from lumbar pain have symptoms 
lasting longer than 3 months. As a consequence, the incidence of lumbar surgery increases. The 
term FBSS refers to a condition of continuing pain and is not meant to imply there was 
necessarily a problem during surgery. The incidence of FBSS is between 20-40%, with an 
increased likelihood with repeated surgery. Increased complexity of back surgery also increases 
the rate of FBSS.  
The goal of the SCS is to alleviate patient suffering and improve the quality of life of 
patients while attempting to reduce the use of chronic opioid therapy. Routine visits with a pain 
management provider may be needed to reprogram the SCS device to provide greater therapeutic 
benefit. The SCS is an effective therapeutic alternative for the treatment of chronic intractable 
pain compared to physical therapy, oral medications, injections, and other surgical interventions 
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such as radiofrequency ablation and intrathecal pain pump (IT pain pump) implantation. This 
raises the question of the effectiveness of the SCS device at reducing pain compared to 
conventional therapies in chronic lumbar pain patients. The purpose of this paper is to determine 
the effectiveness of the SCS device in regards to health care utilization, costs, and overall pain 
relief to the patient. First a background of the different interventions for lumbar pain will be 
discussed, then the literature surrounding different SCS and the different waveforms of the SCS 
will be reviewed, and finally we will discuss final recommendations and further directions that 
the SCS may have in future medical practice.  
Background 
Non-Invasive Modalities. Starting with the least invasive interventions, physical therapy and 
medication management have been the cornerstone in attempts to reduce pain. Qaseem et al 
conducted a systematic review for noninvasive treatments for chronic low back pain, including 
nonpharmacologic treatments, such as exercise and physical therapy. This study proposed 
guidelines to present evidence and provide clinical recommendations for noninvasive treatments 
for low back pain. See Table 1 in Appendices. Patients were identified based on chronicity of 
lumbar pain, being placed in acute, subacute, or chronic subgroups. Nonpharmacologic 
interventions included exercise/physical therapy, motor control exercise (MCE), Pilates, Tai Chi, 
yoga, psychological therapies, multidisciplinary rehabilitation, acupuncture, massage, spinal 
manipulation, use of ultrasound, TENS, and lumbar support.  
Moderate quality evidence showed that exercise/physical therapy resulted in small 
improvements of pain relief and quality of life compared to no exercise/physical therapy. 
Moderate quality evidence showed no clear differences between different exercises/physical 
therapy regimens in more than twenty head-to-head random control trials in patients with chronic 
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lumbar pain. MCE focuses on restoring coordination, control, and strength of muscle groups that 
control and support the spine.5 Low quality evidence demonstrated that MCE moderately 
decreased pain scores and slightly improved function in short- to long-term follow up compared 
with minimal intervention. Low quality evidence showed little to no differences in pain with a 
combination of MCE and exercise/physical therapy versus exercise/physical therapy alone. 
Pilates demonstrated low quality evidence which resulted in little to no clear effects on pain and 
quality of life compared with usual care plus physical activity. Low quality evidence showed that 
yoga resulted in moderately lowered pain scores and improved quality of life. Low quality 
evidence demonstrated that yoga resulted in a small decrease in pain intensity when compared to 
exercise/physical therapy. Low quality evidence showed that progressive relaxation therapies 
moderately improved pain intensity and quality of life compared with wait list controls. Low 
quality evidence showed moderately improved pain relief with cognitive behavioral therapy 
combined with psychological therapies when compared to wait list controls.  
More invasive treatment options were reviewed and the results are as follows: moderate 
quality evidence showed that multidisciplinary rehabilitation slightly reduced long term pain 
intensity and disability compared with usual care. Acupuncture demonstrated low quality 
evidence and was associated with moderate improvements in pain immediately after treatment 
and up to twelve weeks later. Low quality evidence for acupuncture showed small improvements 
in pain relief when compared to NSAIDS, muscle relaxants, and analgesics. Although 
continuous development of new drugs appears on the market for neuropathic pain, these 
medications provide limited relief for patients long-term.5 Low quality evidence showed little to 
now difference in pain between food reflexology and usual care for patients with chronic lumbar 
pain. Low quality evidence demonstrated little to now difference in pain with spinal 
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manipulation compared to sham manipulation. Low quality evidence showed little to no 
difference between ultrasound and sham ultrasound for pain at the end of treatment. Utilization 
of a TENS unit demonstrated low quality evidence and showed no difference between TENS and 
sham TENS for pain intensity or quality of life. Low quality evidence showed no difference 
between TENS and acupuncture in long term pain. Evidence was insufficient to compare lumbar 
support versus no lumbar support.  
According to Dr. Qaseem et al, if nonpharmacologic therapy was inadequate, clinicians 
should consider pharmacologic treatments such as nonsteroidal anti-inflammatory drugs 
(NSAIDs) as first line therapy followed by Tramadol, Duloxetine, or antiepileptics as second line 
therapy in chronic pain patients. Specific antiepileptics, such as Gabapentin and Pregabalin have 
been shown to reduce neuropathic pain after lumbar surgery. Opioids should be considered if the 
aforementioned treatments have failed and only if the potential benefits outweigh the risks. A 
potential weakness in Dr. Qaseem’s review is that the use of opioids for chronic pain requires 
further research to compare benefits and risks of therapy. Information regarding patient 
outcomes such as disability or return to work were also largely unavailable in this study. Baber 
and Erdek also argue that noninvasive treatments such as physical therapy and oral medications 
should be used first line for the management of FBSS. This supports the study conducted by Dr. 
Qaseem, et al in their approach of initially managing patients with FBSS. Physical therapy can 
help optimize gait and posture and can improve muscle strength and function.6 However, studies 
show that the SCS can demonstrate tremendous potential in the management of FBSS when 
compared to other interventions alone. A neuromodulation reference study, the Prospective 
Randomized Controlled Multicenter Trial of the Effectiveness of Spinal Cord Stimulation 
demonstrated improved outcomes with the SCS compared with conventional therapies alone in 
Spinal Cord Stimulation 
 
8 
the treatment of neuropathic pain from FBSS.6 The use of non-invasive therapy is considered 
first line management of FBSS, however, the SCS may provide greater benefit in the long-term.  
Researchers have studied treatments to evaluate the outcomes of regimens in patients 
with FBSS. Treatments reviewed involved medication management, SCS, epidural steroid 
injections, exercise therapy, and psychotherapy. The quality of the assessment and the level of 
evidence were analyzed using a checklist designed by Scottish Intercollegiate Guideline 
Network. See Table 2 in Appendices. Twenty-three articles were reviewed. Studies reported that 
Gabapentin showed more pain reduction than Naproxen in a six-month random control trial. This 
finding was also supported by James Danielle, professor at the University of Adelaide in 
Australia, et al. According to Dr. Qaseem et al, moderate quality evidence showed that NSAIDs 
were associated with a small to moderate improvement in pain intensity. Oral corticosteroids 
may provide a burst of pain relief however long-term use of steroids is not recommended for 
FBSS.3 Both Dr. Baber et al and Dr. Qaseem et al argue that opioid use provides short term 
improvements in pain; however chronic opioid use for noncancer pain is associated with an 
increased morbidity and mortality and does not reliably improve long term pain and function 
scores.6  
Invasive Modalities. After noninvasive treatment options have been exhausted, epidural steroid 
injections, radiofrequency ablations, and intrathecal pain pumps may be considered as an 
alternative treatment approach to FBSS. This section will first discuss current research on 
invasive modalities used to treat FBSS and then compare those approaches to the SCS.  
Epidural Steroid Injections. Epidural steroid injections (ESIs) are one of the most commonly 
performed procedure in pain clinics around the world.6 ESI can be administered by three 
approaches: interlaminar, transforaminal, or caudally. This literature review will focus on 
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transforaminal ESI as it is one of the most common routes of admission. Indications for ESI 
include radiculopathy which is common in FBSS patients. ESIs can be a useful tool for both 
treating the symptoms of lumbar pain after surgery and preventing or delaying the need for 
surgical intervention.9 Most patients would consider pursuing an ESI injection as it may prolong 
the need to pursue lumbar surgery. A randomized, controlled, double blind, active control trial 
was conducted by Dr. Laxmaiah Manchikanti et al to assess the effectiveness of transforaminal 
ESI of local anesthetic with or without steroids in managing chronic lumbar pain in patients with 
disc herniation and radiculitis. 120 patients were randomly assigned to 2 groups. One group 
received a mixture of lidocaine and sodium chloride in their injection, and the other group 
received a mixture of lidocaine, sodium chloride, and betamethasone. Primary outcomes were 
measured with a numerical pain score indicator and the Oswestry Disability Index. The Oswestry 
Disability Index is described as a tool to measure a patient’s permanent functional disability8. A 
high score on the Oswestry indicates increased disability. At 2 years, there was significant 
improvement in all participants in 65% who received local anesthetic alone and 57% who 
received local anesthetic and steroid. When separated into non-responsive and responsive 
categories based on initial relief of at least 3 weeks with 2 procedures, significant improvement 
was seen in 80% in the local anesthetic group and 73% in the local anesthetic with steroid. 
Limitations of this study included a lack of a placebo group. Conclusions of this study found that 
transforaminal ESIs of local anesthetic with or without steroids might be an effective therapy for 
patients with lumbar pain. The evidence illustrates a lack of superiority of steroids compared 
with local anesthetic at 2-year follow up.  
Dr. Kasra Amirdelfan et al conducted a study for FBSS treatments. Treatment for FBSS 
may be generally categorized as physical therapy, oral medications, interventional procedures, 
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SCS, and reoperation. The study concluded that there is weak evidence for improvements in pain 
with medications and reoperation but report also strong evidence for physical therapy and 
interventional procedures, such as ESI injections and the SCS. A weakness noted in the study of 
this study is varying pain reported by patients during their evaluations by providers. The SCS 
showed the strongest evidence and promising results for the long-term treatment of patients with 
FBSS. Optimizing analgesia via pharmacologic interventions in conjunction with ESIs can be 
aimed at treating neuropathic pain.9 These findings align similarly with the results found in the 
studies by Dr. Baber et al, Dr. Cho et al, and Dr. Qaseem et al and suggests that a 
multidisciplinary approach may provide the greatest benefit.  
Ismail Yuce et al conducted a retrospective study for the diagnosis and treatment of 
transforaminal ESIs in lumbar spinal stenosis. In this study, 37 patients were included and treated 
with transforaminal ESI for low back pain related to lumbar stenosis. Regular assessments were 
conducted at 2 weeks, 3 months, 6 months, and 12 months after treatment was administered. 
Visual analogue scale (VAS) and Oswestry Disability Index scales were used to evaluate 
effectiveness of treatment. The average VAS score was 5.1r0.3 before the ESI procedure and 
improved to 2.7r0.1 at the 2-week interval. At 3 months the mean VAS score was 2.8r0.2, and 
at 6 months the score was 3.1r0.1. The average Oswestry Disability Index score was 29.6r0.4 
before the ESI procedure. At the 2-week mark the Oswestry Disability Index was 14.1r0.3. At 
the 3-month interval, the mean score was 15.3r0.5, and at 6 months the mean score was 
24.4r0.2. A strength noted in this study was the use of the VAS and Oswestry Disability Index, 
which are widely and commonly used to evaluate the neurological status and pain complaints of 
patients. This study concluded that transforaminal ESIs are a safe procedure for the nonsurgical 
treatment of lumbar pain. This finding aligns with the results of Dr. Manchikanti et al in that 
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transforaminal ESI may be an effective therapy. This method suggests that 2 ESIs per year may 
be all that is needed to have adequate pain relief and prolong the need for lumbar surgery; 
however, the results from Dr. Manchikanti et al suggests that routine injections of local 
anesthetic and normal saline may be sufficient in reducing pain. This may be feasible for some 
but may be difficult to achieve for others, especially with the elderly. This procedure may be 
preferred support to the indication of surgical treatment.10 This finding aligns similarly with the 
results found in the study by Dr. Amirdelfan et al in that ESIs may prolong the need for lumbar 
surgery.  
A meta-analysis of randomized controlled trials by Dr. Seoyon Yang et al was conducted 
to compare clinical effectiveness of ESI versus conservative treatments for patients with 
radicular lumbosacral pain. Outcomes were measured using VAS, pain scores, Oswestry 
disability index, or successful events. A pain score is defined as a numerical scale, usually 0-10, 
that the patient may use to indicate the level of pain they are experiencing. A lower pain score 
correlates to little or no pain while a higher pain score correlates in severe pain. Successful 
events were defined as the reduction of pain. Conservative treatments were defined by this study 
as bed rest, pharmacologic therapy, exercise, and physiotherapy.  
Six randomized controlled trials that included 249 patients with ESI and 241 patients 
with conservative treatments for lumbosacral pain were identified in this meta-analysis. The 
outcome of the pooled analysis demonstrated that ESI was beneficial for short-term and 
intermediate-term follow up when compared to conservative treatment; however, benefit from 
ESI in the long-term was not maintained. This contradicts the findings in the study Dr. 
Manchikanti et al, who suggests long term benefit from ESIs can be achieved. Successful event 
rates were significantly higher in patients who received an ESI than in patients that received 
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conservative treatments. This also goes against the study conducted by Dr. Qaseem et al who 
suggests that noninvasive treatments alone should provide adequate pain relief. Limitations of 
this meta-analysis resulted from the variation in types of interventions. Another weakness noted 
in this study was the small sample size. A strength noted was the use of the same outcome tools, 
VAS and Oswestry disability index, were used in the study conducted by Ismail Yuce et al. In 
the conclusion of this study, the use of ESI was more effective for alleviating radiating 
lumbosacral pain than conservative treatments in the short-term and intermediate term; however, 
limited benefit was noted in the long term. Patients also reported more successful outcomes after 
receiving an ESI when compared to conservative treatments. In other words, patients who had 
received an ESI could expect to receive about 6 months of pain relief before the need to pursue 
another injection or another intervention.  
Masoud Hashemi et al conducted an observational study to evaluate the effectiveness of 
transforaminal lumbar ESI in patients with unilateral radiculopathy due to lumbar intervertebral 
disc protrusion regarding pain intensity, functional disability, current opioid intake, and patient 
satisfaction. This study was conducted in at a pain management center in Tehran, Iran in 2018. 
Inclusion criteria involved patients greater than age 18 and has had radiculopathy for more than 6 
months due to imagine-proved lumbar intervertebral disc protrusion and no response to 
conservative treatments. Exclusion criteria were spinal canal stenosis, lumbar surgery, and 
inability to communicate in Persian language. Outcomes were measured using VAS, functional 
ability, satisfaction according to the patient satisfaction score, and report current opioid use and 
additional infection and/or surgery. 43 patients were used for this study with a mean age of 59.14 
yeas. 16 patients were male and the rest were female. Patients were monitored for two years after 
initial ESI. Mean VAS prior to intervention was 6.91. After administration of ESI, the mean 
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VAS was 4.67. Mean functional disability before intervention was 47.23 and after intervention 
was 37. Mean patient satisfaction score was 3.07 while 18 cases reported a patient satisfaction 
score level less than or equal to 4. Ten cases reported using opioid analgesia, 23 cases reported 
receiving additional transforaminal ESI, and 11 reported having undergone lumbar surgery. A 
weakness noted in this study was the small sample size and inclusion criteria needed to 
participate in this study. A strength noted was the variety of measured outcomes used, including 
VAS score which was referenced in the studies by Ismail Yuce et al and Dr. Yang et al. 
Conclusions of this study yielded that lumbar ESI injection is an effective nonsurgical treatment 
option with regard to pain relief and improvement in functional ability; however, it is noted that 
about 25% of patients in this study pursued a repeat injection and even fewer proceeded to 
surgical intervention. Other interventions may be used if ESIs cannot be pursued.  
Radiofrequency Ablation. Radiofrequency ablation (RFA), or radiofrequency rhizotomy, is a 
minimally invasive surgery used to treat facet mediated lumbar pain. Lumbar facet pain is 
difficult to identify as it cannot be accurately found by clinical assessment or by imaging 
modalities.14 Successful targeting of the intended nerve is achieved by the use of medial branch 
block (MBB) injections. RFA is a commonly used intervention that selectively cauterizes lesions 
to sensory nerves supplying painful joints identified by MBBs. Results and length of treatment 
may vary as the nerves can regenerate over time. A clinical trial by Y Pevsner et al was 
conducted to assess the role of radiofrequency in the treatment of mechanical pain of spinal 
origin. 122 patients with minimal follow up of 1 year were examined after having undergone a 
radiofrequency heat lesion of the medical branch for spine pain. They were followed up at 1, 3, 
6, and 12 months after treatment. 22 of them were additionally followed up at 18 months. Patient 
outcomes were measured by VAS and by selecting options from a list of options as follows: Pain 
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Free, Good Pain Relief, Moderate Pain relief, or No Effect. At 1 month, 75% of patients had 
significant reduction in pain. At 3 months 71% reported some improvements: 9 patients were 
pain free, 51 patients reported good relief, 27 patients reported moderate relief and 35 patients 
showed no effect. At 6 months, 7 patients remained pain free, 41 patients had good pain relief, 
32 patients had moderate pain relief, and 42 patients showed no effect. At 1 year, 7 patients were 
pain free, 36 patients had good pain relief, 34 patients had moderate pain relief, and 45 patients 
had no effect. The 22 patients that were followed up at 18 months noted significant pain relief. A 
weakness noted in this study was a lack of a placebo group and a high complication rate. This 
study concluded that the RFA procedure has a role in treating patients with lumbar pain; 
however, it should be performed as a second line treatment after conservative treatments have 
failed.  
Dr. Jordan Starr, a physician at the University of Washington, et al conducted a 
retrospective cohort study to describe the trends in utilization and cost of the lumbar RFA and 
joint injections. The patient sample was derived from IBM/MarketScan Commercial Claims and 
Encounters Databases from 2007-2016. Two primary cohorts were identified from patients who 
received lumbar RFA or lumbar facet injections. Results indicated lumbar RFA performed per 
one hundred thousand patients per year increased from 49 to 113, a 130.6% overall increase. 
Lumbar facet injection use increased from 201 to 251 sessions per one hundred thousand 
patients, a 24.9% overall increase. Conclusions found in this study showed consistent growth in 
both the frequency and procedure cost of the lumbar RFA procedure. Similar results were found 
in the study conducted by Dr. Baber et al; however, this contradicts the findings in the study by 
Y Pevsner et al in that the RFA procedure should be used as a second line therapy option.  
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A study conducted by Yuntao Xue et al aimed to investigate the effects of RFA for 
lumbar pain; however, Yuntao Xue et al advocate for the use of endoscopic guidance (ERFA). 
This prospective study enrolled 60 patients that were split into two groups: 30 patients in the 
control group that underwent traditional RFA, and 30 patients that underwent ERFA. VAS was 
used to evaluate the outcomes just as in the studies by Ismail Yuce et al and Dr. Seoyon Yang et 
al. Frequent assessments postoperatively were made at 1 day, 1 month, 3 months, 6 months, and 
12 months. There was no difference in VAS scores in both groups prior to the procedure. VAS 
scores in all other postoperative times were significantly lower than preoperative values in both 
groups. No significant differences were noted between the two groups in VAS at day 1, 1 month, 
and 3 months postoperatively; however, the ERFA demonstrated significant benefit at 3-month 
and 6-month intervals. The VAS scores of the 1 year follow up in the ERFA group was higher 
than that of the control group. Complications in the ERFA group were also noted to be lower 
than the control group. Controlled MBB was the only diagnostic method to identify patients. A 
potential weakness in this study was the rate of false positives of uncontrolled MBB. Yuntao Xue 
et al concluded that ERFA has advantages of accurate positioning, more thorough denervation, 
fewer complications, lower risks, and better long-term efficacy. While Yuntao Xue et al focused 
primarily on EFRA, in general, the RFA procedure may provide long term benefit. This 
conclusion is similar to the results found in the studies by Dr. Jordan Starr et al and Y Pevsner et 
al.  
Intrathecal Pain Pumps. When minimally invasive interventional pain management techniques 
have failed, continuous intrathecal analgesic administration may be considered. Intrathecal pain 
pumps (IT pain pumps) are implantable devices with a reservoir that store pain medication, such 
as Morphine, Hydromorphone, Ziconotide, Fentanyl, or Bupivacaine, and release it at a 
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continuous rate.17 A trial is often recommended which involves placement of a temporary lead 
and a bolus dose of the desired medication. Patients may choose to continue for implantation of 
the IT pain pump pending a successful trial. The pump is implanted subcutaneously, usually in 
the lower abdomen, and the medication is fed through a lead which releases it into the 
cerebrospinal fluid (CSF).18 As a result, the IT pain pump can offer quick and effective pain 
relief. If appropriate, patients may also have the option to administer a bolus dose of medication 
a few times per day. Depending on how much medication is needed, patients should follow up 
with their pain specialists for refill of their reservoirs every 1-2 months. Ultrasound guidance 
allows for accurate delivery of medication during a refill. Complications of the IT pain pump 
may arise in the form of a catheter tip granuloma, which occurs over a long period of time and 
may obstruct passage of medication.17  
Dr. Nikolai Rainov et al conducted a clinical trial to assess the long-term intrathecal 
infusion of drug combinations for chronic back and leg pain. This study represents a long-term 
evaluation of the treatment regimen consisting of Morphine, mixed with Bupivacaine, Clonidine, 
or Midazolam in patients with chronic nonmalignant back and leg pain. 26 patients have been 
followed up for 3.5 years. Combination of Morphine with a second drug was used in 10 cases, 
Morphine with 2 additional drugs in 12 cases, and Morphine with 3 additional drugs in 4 cases. 
Patient outcomes were measured using VAS. 19 patients reported excellent or good treatment 
results, 6 patients had sufficient results, and only 1 patient mentioned poor therapeutic effects. A 
weakness noted in this study was a small number of participants. A strength noted was the use of 
standardized pain scales. Mean Morphine doses had to be increased from 1.2mg at baseline to 
5.1mg at 2 years due to tolerance development and disease progression. This study suggests that 
IT polyanalgesia employing Morphine combined with an additional non-opioid drug can have a 
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favorable outcome in patients with complex chronic pain of spinal origin. In other words, 
combination therapy using different classes of medications may provide adequate pain relief. 
A comprehensive literature review conducted by Dr. Timothy Deer et al to evaluate the 
evidence for Morphine and Ziconotide as first line IT pain pump analgesics for patients with 
chronic pain. The literature reviewed included noncontrolled, prospective, retrospective, and 
observational studies. Methods used for this study involved a Medline search for “Ziconotide” or 
“Morphine” and “intrathecal” and “chronic pain.” The literature supports the use of Morphine 
and Ziconotide as first line treatments for IT therapy. This aligns with the 2016 Polyanalgesic 
Consensus Conference (PACC) guidelines which recommend either Morphine or Ziconotide as 
first line IT monotherapy for chronic pain; however, one consensus point emphasized Ziconotide 
use in patients with chronic, non-cancer related pain. PACC guidelines recommend conservative 
initial dosing strategies. Due to its narrow therapeutic window and contraindication in patients 
with psychosis, Ziconotide requires careful dosing. IT Morphine administration may be 
associated with serious side effects, such as respiratory depression.17 Data is needed to further 
understand the benefits and risks associated with initial IT pain medication in diverse chronic 
pain patients. A strength noted in this study was patient contribution to help identify which 
medication would work best for them. This study concluded that both Morphine and Ziconotide 
are recommended as first line IT monotherapy for cancer related and non-cancer related pain. 
The choice should take into consideration patient characteristics and the risks versus benefits of 
each medication. Combination therapy may be considered only after the failure of IT Morphine 
or Ziconotide monotherapy, which is a result shared by findings of Dr. Rainov et al.  
Dr. Denise Wilkes, physician at the University of Texas, et al had conducted a 
retrospective study to assess the success of microdosing Morphine method in a community pain 
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clinic stetting by monitoring follow up frequency, dose escalation, and monotherapy/polytherapy 
ratio.  The microdose method involves a pretrial reduction of systemic opioids followed by a 
period of abstinence.18 IT Morphine is then started at doses less than 0.2mg per day. Systemic 
opioid abstinence is then continued after the IT pain pump has been implanted and IT Morphine 
monotherapy has started. 60 patients were selected who had completed a microdose regimen and 
had an IT pain pump implanted. Dose changes, pain scores, side effects, max doses, and duration 
of therapy was recorded. Out of 60 patients, 35 were successfully managed on Morphine 
microdose monotherapy. No additional oral medication was needed to control pain. Significant 
reductions in pain scores were noted, going from 7.4r0.32 before microdose to 4.8r0.3 after 
microdose therapy. Any weakness in the study was related to the retrospective nature. Selection 
of patients who were able to wean and willing to commit to a microdose plan can affect the 
outcome. Another weakness noted was that the study primarily focused on Morphine 
microdosing and did not evaluate the success of other regimens such as Hydromorphone or 
Ziconotide, as in the studies conducted by Dr. Deer et al and Dr. Rainov et al. A strength noted 
in this study was the multiple disciplinary approach, such as physical therapy and follow up 
visits with pain specialists, established after microdose therapy has been initiated. Physical 
therapy was highly encouraged as a conservative treatment by both Dr. Qaseem et al and Dr. 
Amirdelfan et al.   
Spinal Cord Stimulation. All interventions discussed thus far have been aimed to reduce 
neuropathic pain in chronic lumbar pain patients. Chronic neuropathic pain is still not 
extensively understood which makes it challenging to treat. The present alternative treatment 
considered as the gold standard for many types of chronic neuropathic pain is the spinal cord 
stimulator (SCS). There are also many waveforms that the SCS can administer to reach 
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therapeutic effect. As previously mentioned, the SCS appeared into clinical practice in the 1960s 
with the concept of gate control theory (GCT), which was first conceptualized by Patrick Wall 
and Ronald. Melzack.19 Today, the technology of the SCS is more refined. Wall and Melzack 
theorized that the nociceptive signal would be inhibited by antidromic activation of collateral 
myelinated alpha-beta fibers in the dorsal columns.19 The first reported clinical application of the 
dorsal column stimulation came two years later. At the time, the SCS was thought to act merely 
at the spinal segment level. However, GCT theory did not take into account two evident 
contradictions. The first is that SCS should be more effective in controlling acute nociceptive 
pain, which is not the case. Secondly, Wall and Melzack’s theory is not able to explain the pain 
free interval that is often noticed after discontinuation of stimulation. For these reasons, GCT 
theory is more and more inconsistent to explain the mechanism of action of the SCS. The SCS is 
deemed to neutralize the overexcitability of wide dynamic range neurons in the dorsal horn by 
increasing GABA.19 Wide dynamic range neuron wind-up caused by excessive nociceptive 
inputs is believed to trigger the lateral pain pathway, giving the start to the abnormal 
transmission of pain sensation to the brain. To this point, it remains unclear whether the SCS 
rebalancing effect of the system occurs solely as a result of presynaptic inhibition of wide 
dynamic range neurons through antidromic activation or if it is due to most complex combined 
pre/postsynaptic phenomena.19  
The SCS consists of a small battery that emits electrical impulses through 2-4 leads with 
metal contacts. The battery is placed subcutaneously and the leads are placed in the epidural 
space via fluoroscopy. Electrical signals convey the sense of paresthesia to the patient effectively 
blocking pain signals to the brain with success rates ranging from 50-75%.4 However, before the 
SCS is implanted, patients must complete a one-week trial in order to determine if it will provide 
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benefit. The most common complications to the SCS treatment include lead migration, infection, 
and pain over the implant site.2 The most common indication for the SCS is FBSS, CRPS, 
radicular and nerve root pain, postherpetic neuralgia, pain due to peripheral nerve injury, 
intercostal neuralgia, and phantom pain.21 SCS main contraindications include infection, 
coagulopathy, spinal stenosis, psychiatric disorders, and substance abuse. After a diagnosis has 
been established and a patient wishes to pursue the SCS, they must first complete a trial phase. 
The trial phase consists of temporary leads implanted via fluoroscopy. The leads are attached to 
an external battery which mimics the effects of the SCS. The battery and surgical incisions are 
secured by a dressing. If the patient passes the trial, then they are able to schedule their implant 
date. Patients may also have the choice between a rechargeable and a non-rechargeable SCS 
device, depending on the brand.  
Dr. Zucco et al conducted an observational, multicenter, longitudinal, ambispective 
randomized controlled trial to assess the cost effectiveness and cost utility of SCS in patients 
with FBSS refractory to conventional therapies. 80 patients were recruited and received the SCS 
and conventional therapy treatments. Patients were monitored for 24 months after implantation 
of the SCS. Outcomes such as pain intensity, Oswestry Disability Index, quality of life scales, 
and direct costs before and after the SCS were measured. After implantation, quality of life had 
significantly improved. Societal costs increased by nearly 50% per patient per year. Accordingly, 
this study suggests that if patients are willing to pay for the procedure, then the implantation 
would be cost effective in the long term. A weakness noted in this study was the small 
population size. This study concluded that the SCS combined with conventional therapies may 
provide good value for money.  
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A recent study conducted by Ontario Health (Quality) was done to assess the 10-kHz 
high frequency SCS in adults with chronic noncancer pain that was refractory to medical 
management. This included an evaluation of effectiveness, the budget impact of publicly funding 
10-kHz high frequency SCS, and patient preferences and values. This study involved a 
systematic literature search and a systematic economic literature review. Seven publications were 
included in this study. The risk of bias was assessed of each study using the Cochrane Risk of 
Bias and ROBINS-I tools, and the quality of the body of evidence according to the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE) Working Group 
criteria. Analysis of the 5-year budget impact of publicly funding 10-kHz high-frequency SCS in 
Ontario for adults with chronic noncancer pain was performed. Results indicated a GRADE 
score of “moderate” that 10-kHz high frequency SCS likely provides reductions in pain intensity 
and functional disability, and improvements in quality of life in people with chronic noncancer 
pain. With a GRADE score of “low,” patients may reduce their opioid consumption with 10-kHz 
high-frequency SCS. The two included economic evaluations found that 10-kHz high frequency 
SCS was cost-saving compared with the conventional SCS. Limited evidence was found about 
the effectiveness of 10-kHz high-frequency SCS in people who have first tried and failed 
conventional SCS at lower frequencies as a cost-effective analysis was not conducted. The 
comparisons in the randomized controlled trials all involved conventional low-frequency SCS as 
the active comparator. There were no trials of 10-kHz high-frequency SCS compared with a 
sham arm to evaluate placebo response. For adults with chronic noncancer pain that was 
refractory to medical management, 10-kHz high frequency SCS was effective in relieving pain, 
reducing disability, and improving quality of life.  
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A study by Dr. Terje Kirketeig of Uppsala University Hospital in Sweden was conducted 
to review outcomes using burst SCS stimulation in the treatment of chronic, intractable pain. The 
concept of burst SCS was first introduced in 2010 by Dirk DeRidder and colleges, targets the 
dorsal columns in stimulus bursts comprised of five 1-ms pulses with an intraburst frequency of 
500Hz, delivered with a frequency of 40Hz in a passive recharging paradigm to maintain charge 
balance across the electrical contacts.22 When the burst SCS pattern was electrically applied to 
the dorsal columns at adequate settings, it was effective at producing analgesia without the need 
for paresthesia. A narrative clinical literature review was conducted utilizing search terms 
including key words for burst spinal cord stimulation. Synthesis and reporting of data from 
publications including an overview of comparative SCS outcomes was conducted. Medline and 
Embase databases were used. Results of this study found that burst SCS provided greater pain 
relief over conventional stimulation. This was demonstrated in multiple studies which included 
blinded, sham-controlled, and randomized trials. Additionally, burst stimulation impacts multiple 
dimensions of pain, including somatic pain as well as emotion and psychological elements. 
Patient preference is also geared toward burst SCS over conventional SCS due to increased pain 
relief, a lack of paresthesia, and impression of change in condition. Burst SCS has been shown to 
be both statistically and clinically superior to conventional SCS and may provide additional 
benefits through different mechanisms of action. Conventional SCS was also found to be inferior 
in the study conducted by Ontario Health; however, Ontario Health was comparing results with 
high frequency SCS. There is a high level of clinical evidence for the efficacy of burst SCS on 
pain intensity after one year of therapy in patients suffering from a variety of chronic pain 
conditions. Moreover, there are many blinded, sham-controlled randomized controlled trials 
indicating clinical superiority over both placebo and conventional SCS. The overall level of 
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evidence in trials reviewed for this study was variable, ranging from high-quality prospective 
trials with long follow up periods to a number of low- to medium-quality trials. Although there is 
data on a variety of neuropathic pain conditions, future studies should also better focus on 
individual pain conditions, such as FBSS, CRPS, peripheral neuropathies, postsurgical chronic 
pain, ischemic pain conditions, visceral pain, and post stroke pain.  
Another study, conducted by Dr. Jay Karri et al, aimed to provide evidence for various 
SCS waveforms- including burst, high frequency, and conventional relative to each other for 
treating chronic lumbar pain. To conduct this study, Dr. Karri et al performed a systematic 
review based on conventional methodology described by Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISM). PubMed, Medline, Cochrane Library, priory 
systematic reviews, and reference lists were screened for all randomized trials and prospective 
cohort studies comparing different SCS waveforms for treatment of chronic lumbar pain. In 
terms of analgesic efficacy, five studies reported pain scores and standard deviations for patients 
who received burst or conventional waveforms. These studies were pooled for meta-analysis. 11 
studies were identified that included waveform comparisons for treating lumbar pain. Of the 11, 
6 studies compared burst versus conventional, 2 studies compared burst versus high frequency, 
and 3 studies compared conventional versus high frequency. A meta-analysis of 5 studies 
comparing burst versus conventional SCS was conducted. Meta-analysis of these five trials 
revealed a significant reduction in pain scores favoring burst over tonic waveforms. These results 
support the findings by Dr. Kirketeig et al. In regards to conventional versus high frequency 
SCS, 3 studies showed both meaningful pain reduction with high frequency waveforms relative 
to baseline and noninferiority of high frequency waveforms relative to conventional SCS. This 
finding agrees with the finding from the study conducted by Ontario Health (Quality) et al. There 
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is a dearth of evidence comparing burst and high frequency waveforms for the treatment of 
chronic lumbar pain. Two studies were found to compare burst versus high frequency 
stimulation; however, there was no meaningful superiority of either waveform in treating back 
pain but found that burst was superior to high frequency stimulation in reducing leg pain at 3- 
and 12- month intervals. Of note, a few studies that reported benefit with the use of burst 
waveform were not included due to lack of obtaining standard deviations for the reported mean 
pain scores. A sensitivity analysis was performed on the 5 studies included for the burst versus 
conventional meta-analysis. The analysis was performed by sequentially removing each 
individual trial and evaluating how it affected the pooled estimate of the primary outcome. This 
process failed to find a significant difference. A limitation noted in this study was that both 
randomized controlled trials and prospective cohort studies were included in this meta-analysis. 
Several studies included a high risk of bias in at least one domain.  
Dr. Charles Odonkor et al performed a retrospective cohort study to appraise literature 
evidence supporting the health care resource utilization and cost effectiveness of the SCS 
compared with conventional therapies for chronic lumbar and leg pain. Databases from PubMed, 
Medline, Embase, CINAHL, and Rehabilitation and Sport Medicine were used using the terms 
“spinal cord stimulation,” “chronic pain,” “back pain,” “patient readmission,” “economics,” and 
“costs and cost analysis.” After initial screening of 204 studies, 11 studies meeting inclusion 
criteria were analyzed, representing 31,439 SCS patients and 299,182 conventional therapy 
patients. Conventional therapies were defined as medication management, physical therapy, 
ESIs, trigger point injections, nerve blocks, chiropractic treatments, massage therapy, 
acupuncture, and surgery. Primary outcome measures were cost and health care resource 
utilization. The most commonly reported measures of health care resource utilization were 
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annual imaging rates, opioid usage, and hospitalizations. The mean age was 53 years for the SCS 
and 55.6 years for conventional therapies. In six of 11 studies evaluating SCS versus 
conventional therapies in relation to cost implications/quality outcomes, SCS was associated 
with favorable outcomes and found to be more cost effective than conventional treatment 
approaches for chronic lumbar pain. For the remaining studies, two studies were retrospective 
reviews of claims data, one study compared costs of rechargeable versus non-rechargeable SCS 
systems, another compared costs of imaging amount patients with SCS implants versus patients 
projected to require SCS imaging in one year, and the other study used values from the published 
literature to create cost analysis models from the SCS cost estimates were derived. The most 
common indication for the SCS is FBSS, which was evaluated in six of the 11 studies. Other 
indications included CRPS, peripheral artery disease (PAD), refractory angina pectoris (RAP), 
chronic back and leg pain, chronic axial lumbar pain, degenerative disc disease, radiculitis, 
neuropathic leg and back pain, and chronic benign pain syndrome. Several drivers of high 
resource utilization in SCS therapy were identified, which included cost of imaging, costs related 
to management of complications, and delay in time to delivery of SCS therapy. In regards to pain 
relief, three of 11 studies included pain relief outcomes. There was a large discrepancy in 
reported pain relief outcomes depending on the type of study and population evaluated; however, 
SCS treatment was shown to decrease the numerical rating scale score at 24 months from 7.56 to 
5.11, and this pain reduction was both statistically and clinically significant. In six of 11 studies 
analyzing costs associated with SCS therapy, SCS was associated with favorable outcomes in 
terms of cost-effectiveness and health resource utilization compared to conventional therapies in 
the long term; however, in the short term the SCS was found to be less cost effective to patients. 
Adverse events with SCS were reported in three of 11 studies. When compared to lumbar 
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surgery, the SCS resulted in a lower complication rate of 8.6% versus 16.52% for lumbar 
surgery. Other types of complications included renal, cardiac, neurological, pulmonary, deep 
vein thrombosis/pulmonary embolism, systemic infection, and battery site wound infection. The 
overall costs between the SCS and lumbar surgery were similar but the SCS is associated with 
fewer complications and improved outcomes. A strength noted in this study was the inclusion of 
comparative health utilization of the SCS versus conventional therapies. The use of clinical 
registries also allowed for real time tracking for SCS patients to collect data. A limitation noted 
was the upfront costs of the SCS procedure which could guide care of patients for their chronic 
pain. The systematic review of health care resource utilization in the treatment of chronic limb 
and back pain underscores low to fair evidence favoring SCS over conventional therapies as a 
more cost-effective modality with less resource utilization.24 For the treatment of chronic lumbar 
and leg pain, the majority of studies are of fair quality, with level 3 to 4 evidence in support of 
SCS as potentially more cost-effective than conventional therapies, with less resource 
expenditure but higher complications rates. This result shares similarities with the studies 
conducted by Dr. Zucco et al, Dr. Kirketeig et al, Dr. Karri et al, and Ontario Health (Quality). 
Methods 
PubMed and Google Scholar databases were used for this study. Studies that were mostly 
published from 2018 to 2021 were reviewed using the following terms, “spinal cord 
stimulation,” “chronic low back pain,” “conservative treatments,” “costs and cost analysis,” and 
“failed back surgery syndrome.” The database search was time limited to the last 3 years to make 
sure the literature review was current and up to date. Older articles were used to provide 
background information. The basic search strategy was modified for each database to optimize 
results for each database. Additional sources include direct contact with an expert pain specialist 
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for their input. Studies that met the following criteria were included: patient population suffering 
from chronic lumbar pain, patients treated with SCS implant and/or conventional therapies and 
medical management, studies evaluating the economics and/or cost effectiveness of SCS 
compared with conventional therapies, and studies evaluating hospitalization and health resource 
utilization. Exclusion criteria involved any studies with children, pregnant women, patients with 
significant psychological disorders, and patients who are not able to sign informed consent. The 
Population, Intervention, Comparison, and Outcome (PICO) framework informed study 
screening. See Table 3 in Appendices. Primary outcome measures were health care utilization 
and costs.  
Discussion 
This literature review of the treatment of chronic lumbar pain underscores fair evidence favoring 
the SCS over conventional therapies in regards to health care utilization and over all pain relief. 
Both Dr. Qaseem et al and Dr. Baber et al agree that noninvasive treatment options should be 
used first line; however, Dr. Baber et al suggest that the SCS providers greater pain relief and 
reduced overall cost to the patient than non-pharmacologic noninvasive treatments. According to 
Dr. Qaseem et al, if non-pharmacologic intervention fails, medications such as NSAIDS, 
Tramadol, Duloxetine, Gabapentin, and Pregabalin may be used. This statement contradicts the 
claims of Dr. Amrdelfan et al who found low quality evidence in managing pain with oral 
medication alone. Both Dr. Qaseem et al and Dr. Baber et al argue that opioid use may provide 
short term pain relief but should not be used as a long-term treatment option.  
Dr. Amirdelfan et al suggests that physical therapy and other interventions, such as ESI, 
should be started as first line therapies for chronic lumbar pain. This is in agreement with Ismail 
Yuce et al who also suggest that ESIs are a safe alternative for nonsurgical treatment for lumbar 
Spinal Cord Stimulation 
 
28 
pain. A similar result was also found by Masoud Hashemi et al; however, in that study, there was 
a significant percentage of participants that pursued a repeat injection and even some that 
required repeat surgery. In line with the hypothesis of ESI for lumbar pain, Dr. Yang et al 
concluded that ESI injections provide adequate pain relief in the short- and intermediate- term, 
but minimal evidence exists for long term benefit. This contradicts the findings in the study Dr. 
Manchikanti et al where long-term benefit was found with ESIs. A strength noted in the studies 
of Ismail Yuce et al, Masoud Hashemi et al, and Dr. Yang et al was the use of the VAS score as 
a standard to measure the outcome of patient relief and satisfaction.  
In regards to the RFA procedure, Dr. Starr et al believes that the RFA procedure produces 
greater relief and fewer complications than facet injections. While Dr. Baber et al notes there is 
benefit with the RFA procedure, he argues that the SCS device would provide greater benefit. 
Yuntao Xue et al also argues that RFA can provide adequate pain relief; however, ERFA was 
thoroughly examined. On average ERFA provides significant benefits at 3- and 6-month 
intervals. Yuntao Xue et al also utilized the VAS score to measure patient outcome. This finding 
contradicts the results by Y Pevsner in that the RFA procedure should be used as a second line 
therapy after conventional therapies have been trialed.  
The studies conducted by Dr. Deer et al and Dr. Wilkes et al argue that IT pain pumps 
with Morphine may be more effective at treating chronic lumbar pain; however, Dr. Rainov et al 
suggests that intrathecal Morphine combined with another non-opioid medication may provide 
adequate benefit. According to Dr. Deer et al, Ziconotide may be used in place of Morphine but 
the procedure itself is more invasive than the SCS. Another limiting factor of the IT pain pump is 
that the patient can still potentially be on long term opioid use. This goes against the 
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recommendations set by Dr. Qaseem et al and Dr. Baber et al. The SCS does not administer 
medication and therefore the potential for abuse is limited.    
In regards to the SCS, there are many waveforms to choose from for the patient. The 
study conducted by Ontario Health (Quality) et al found significant evidence that 10-kHz high 
frequency SCS may reduce pain and functional disability when compared to conventional SCS. 
It was also found that high frequency SCS may also reduce opioid consumption in the long term 
which aligns with the results found by Dr. Baber et al. When compared to conventional SCS, Dr. 
Kirketeig et al found that the burst waveform of the SCS provided greater pain relief in patients 
with chronic lumbar pain. This result was also found in the study conducted by Dr. Karri et al 
who also found that the burst waveform provided greater benefit than conventional SCS. Dr. 
Karri et al had also found significant improvements when comparing high frequency SCS to 
conventional SCS, a result shared with Ontario Health (Quality) et al. Dr. Karri et al has also 
compared the effectiveness of high frequency SCS and burst waveform SCS and had found that 
there are minimal differences between them. Regardless of waveform, the SCS has found to be a 
promising alternative to conventional pharmacologic and surgical interventions for chronic 
lumbar pain. The study conducted by Dr. Odonkor et al and Dr. Zucco suggests that the SCS 
may provide higher incremental monetary value by decreasing long term chronic pain burden.  
Any recommendation for the SCS as a cost effective first line therapy for chronic low 
back pain is limited by the need for more robust evidence regarding related resource utilization 
and therapeutic benefits over conventional treatment modalities. Chronic pain occurs over time, 
and it would be beneficial to know at which point in the pain timeline process that the SCS 
would yield the highest return per unit cost of therapy per patient. Variations in reported pain 
relief from SCS versus conventional therapies could be due to several reasons, including 
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differences in study populations and settings, unmeasured latent factors and confounders, and 
study designs. Further research studies are needed to get a better understanding of the SCS can 
be better utilized. Further studies are also needed that may focus on relative cost effectiveness of 
different SCS waveforms versus conventional therapies. 
Conclusion 
The goal of this paper was to compare the effectiveness of the SCS versus conventional therapies 
for patients with chronic lumbar pain. Thus far, different interventions have been discussed for 
the treatment of chronic lumbar pain. Each intervention has been discussed in detail and while 
each modality may provide benefit alone, a multidisciplinary approach may provide the greatest 
benefit. The outcomes all suggest that noninvasive treatments should be trialed first before 
moving on to more invasive interventions for lumbar pain. Noninvasive treatments include 
pharmacologic intervention, physical therapy, and routine exercise, which have been proven to 
reduce pain slightly. Further studies for specific medication management are needed to find the 
best combination for pain relief.  
The results all suggest that ESIs provide adequate pain relief in the short- and 
intermediate term but does not provide much benefit in the long term. Patients with chronic 
lumbar pain may receive benefit from ESIs but repeat injections are often needed. ESIs may also 
post pone the need for surgery. A strength noted in these studies included the use of the VAS 
scale to standardize patients’ pain levels. The studies concluded that the RFA procedure may 
have significant reductions in pain, and even greater improvement with ERFA. Pain relief was 
greatest at 3 and 6 months; however, there is limited evidence for significant pain relief lasting 
longer than 6 months; however, some believe the RFA procedure should be used after other 
therapies have failed. The outcome for the studies suggests that an IT pain pump filled with 
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Morphine may provide significant pain relief; however, this intervention is the most invasive and 
would still require the need for monthly refills to provide benefit. IT pain pumps filled with 
Morphine and another non-opioid medication provide adequate pain relief. Finally, the studies 
conducted on SCS thus far all suggest that the SCS is more cost effective, provides significant 
pain relief, and reduces overall health care utilization than conventional therapies. 
The topic of chronic pain may be difficult for patients to grasp and a caring approach is 
often needed. Fortunately, there exists a wide variety of treatments for chronic lumbar pain and a 
multimodality treatment plan is recommended. Treatment plans should start with the least 
invasive and moving on to more invasive treatment plans. Patient risks and benefits should 
always be discussed with the patient. The SCS can provide adequate pain relief but even more so 
when paired with other interventions, such as physical therapy, medication management, and 
ESIs. Further studies are needed to assess multiple interventions effectiveness with concurrent 
use of the SCS. Not every case of lumbar pain is an indication for the SCS but when it is, the 
long-term benefit from the SCS may outweigh the risks. It is important to understand that the 
SCS does not change the physiology of a patient’s spine but rather helps mask pain. Patients may 
elect for a repeat lumbar surgery if the SCS is not indicated or cannot be pursued. Routine follow 
up with a pain specialist is recommended and will allow patients to view their treatment options 
while in a controlled and safe environment. The SCS may result in better health related quality of 
life and quality adjusted life years for patients suffering with chronic lumbar pain when 
combined with conventional therapies.  
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Table 3. PICO Framework for Screening Studies 
CRITERIA INCLUSION 
Population The population was composed of adults (age greater than 18 years) of both 
genders diagnosed with chronic lumbar pain 
Intervention Spinal cord stimulation therapy 
Comparison Conventional therapies (medication, physical therapy, ESI, radiofrequency 
ablation, IT pain pump)  
Outcome Improvement in total medical expenditure related to chronic pain, average 
duration of pain relief, percent reduction of opioids, improved quality of 
life, reduction of adverse events, and improved utility score with the SCS  
 

